Pharmaceutical sponsor
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Clinical Trials
Studies where Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. is the lead sponsor: its pipeline by phase, what is enrolling now and where. Studies it supports as a collaborator are in the search.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 16Cutaneous Lupus Erythematosus (CLE)
This Study Will Evaluate the Effect and Safety of 626 in Patients With CLE
This study aims to evaluate the efficacy and safety of subcutaneous (SC) 626 versus placebo in adult participants with cutaneous lupus erythematosus (CLE).
- Trial name
- NCT07900867
- Where
- 2 sites in China
- Volunteers
- 140 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Dermatitis, Atopic
Evaluation of 611 in Chinese Children With Moderate to Severe Atopic Dermatitis(AD)
This study is a 2-part (parts A and B) study.The primary objective of the study is to evaluate the efficacy of 611 in Chinese Children with moderate to severe atopic dermatitis (AD).
- Trial name
- NCT07767253
- Testing
- 611
- Where
- 5 sites in China
- Volunteers
- 246 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Ulcerative Colitis (UC)
The Purpose of This Study is to Evaluate the Efficacy and Safety of 627 in the Treatment of UC
This study will evaluate the efficacy and safety of 627 in patients with UC.
- Trial name
- NCT07507513
- Testing
- 627
- Where
- China
- Volunteers
- 288 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Gout Arthritis
A Study of SSGJ-613 in Gout Participants Initiating Urate-Lowering Treatment
The purpose of this study is to determine the efficacy and safety of recombinant anti-interleukin-1β humanized monoclonal antibody injection in Chinese gout participants Initiating Urate-Lowering Treatment
- Trial name
- NCT07708181
- Testing
- SSGJ-613 100 mg Q12W, SSGJ-613 200 mg Q12W, SSGJ-613 100 mg Q4W
- Volunteers
- 200 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
AD
A Phase I Study of SSGJ-716 in Healthy Adults and Participants With Moderate-to-Severe Atopic Dermatitis
The purpose of this Phase 1 study is to evaluate the safety and tolerability of a new investigational drug called SSGJ-716 in healthy adults and in participants with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT07693738
- Testing
- SSGJ-716
- Where
- China
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Axial Spondyloarthritis, Non-Radiographic
A Study to Evaluate the Efficacy and Safty of 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA)
This study will evaluate the efficacy and safety of 608 in patients with nr-axSpA.
- Trial name
- NCT07349329
- Testing
- 608
- Where
- China
- Volunteers
- 380 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Asthma
Efficacy and Safety Study of 610 in Patients With Severe Asthma
The primary objective of the study is to evaluate the efficacy and safety of 610 in Chinese adults with severe asthma.
- Trial name
- NCT06323213
- Testing
- 610
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Ankylosing Spondylitis
A Study to Evaluate the Efficacy and Safety of 608 in Adult Subjects With Active Ankylosing Spondylitis(AS)
This study will evaluate the efficacy and safety of 608 in patients with AS.
- Trial name
- NCT07261644
- Testing
- 608 dose
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Systemic Lupus Erythematosus (SLE)
The Purpose of This Study is to Evaluate the Efficacy and Safety of 626 in the Treatment of SLE
This study will evaluate the effect and safety of 626 in patients with SLE
- Trial name
- NCT07185269
- Testing
- 626
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Pulmonary Disease, Chronic Obstructive (COPD)
Evaluation of 611 in Chinese Adults Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
The objective of the study was to evaluate the efficacy and safety of 611 in Chinese adults with moderate to severe COPD.
- Trial name
- NCT07039669
- Testing
- 611
- Where
- 4 sites in China
- Volunteers
- 594 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.